Head to Head Analysis: H-CYTE (OTCMKTS:HCYTD) vs. INVO Fertility (NASDAQ:IVF)

INVO Fertility (NASDAQ:IVF) and H-CYTE (OTCMKTS:HCYTD) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, dividends and valuation.

Valuation & Earnings

This table compares INVO Fertility and H-CYTE”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
INVO Fertility	$6.53 million	0.41	-$9.10 million	($630.30)	0.00
H-CYTE	$1.61 million	0.32	-$4.80 million	N/A	N/A

H-CYTE has lower revenue, but higher earnings than INVO Fertility.

Profitability

This table compares INVO Fertility and H-CYTE’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
INVO Fertility	-417.02%	N/A	-92.42%
H-CYTE	-450.40%	N/A	-777.68%

Insider and Institutional Ownership

12.0% of INVO Fertility shares are owned by institutional investors. 0.7% of INVO Fertility shares are owned by company insiders. Comparatively, 5.2% of H-CYTE shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Risk and Volatility

INVO Fertility has a beta of 2.64, suggesting that its share price is 164% more volatile than the S&P 500. Comparatively, H-CYTE has a beta of 1.12, suggesting that its share price is 12% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for INVO Fertility and H-CYTE, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
INVO Fertility	1	0	0	0	1.00
H-CYTE	0	0	0	0	0.00

Summary

INVO Fertility beats H-CYTE on 7 of the 9 factors compared between the two stocks.

About INVO Fertility

INVO Bioscience, Inc., together with its subsidiary, a healthcare services fertility company, provides assisted reproductive technology solutions worldwide. It offers INVOcell, a medical device that allows fertilization and early embryo development to take place in vivo within the woman’s body. The company was founded in 2007 and is based in Sarasota, Florida.

About H-CYTE

H-CYTE, Inc., a biopharmaceutical company, develops and delivers various treatments for patients with chronic respiratory and pulmonary disorders in the United States. The company develops and implements treatment options in autologous cellular therapy to treat chronic lung disorders. It has a product supply agreement with Rion, LLC to develop and distribute a biologic for chronic obstructive pulmonary disease. The company is headquartered in Tampa, Florida.